PET Imaging of Inflammation and Lipid Lowering Study
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hypercholesterolemia
- Hypercholesterolemia, Familial
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double-blind, placebo controlled.Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
Up-regulation of SST2 in activated macrophages represents a novel imaging target for measuring vascular inflammation, which has been previously examined in atherosclerosis using 68Ga-DOTATATE. To test the hypothesis that 68Ga-DOTATATE can quantify drug-induced changes in arterial inflammation, patie...
Up-regulation of SST2 in activated macrophages represents a novel imaging target for measuring vascular inflammation, which has been previously examined in atherosclerosis using 68Ga-DOTATATE. To test the hypothesis that 68Ga-DOTATATE can quantify drug-induced changes in arterial inflammation, patients with stable cardiovascular disease or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein (LDL) cholesterol despite high-intensity statin treatment will undergo serial carotid 68Ga-DOTATATE PET-magnetic resonance imaging (MRI) in a double-blind, two-arm, parallel-design, placebo-controlled study.
Tracking Information
- NCT #
- NCT04073797
- Collaborators
- Cambridge University Hospitals NHS Foundation Trust
- Wellcome Trust
- Investigators
- Principal Investigator: Jason M Tarkin, MBBS PhD University of Cambridge
Get Well Soon